"The closest comparison drugs I can think of for apabetalone's mutliple genes/pathways mechanism of action are for drugs that are agonists or partial agonists of certain nuclear hormone receptors like peroxisome proliferator-activated receptors (PPARs) and farnesoid-X-receptor (FXR)."

You can even add Amarin's Vascepa (icosapent ethyl) to this list of drugs that simultaneoulsly modulate multiple targets and pathways. The biology of omega-3 fatty acid metabolism is very complex. Although initially developed as a triglyceride (TG) lowering drug, Vascepa in REDUCE-IT elicited robust MACE reduction independent of baseline TG level or change in TG. In slide 14 of Amarin's most recent investor presentation:

"Clinical effects of Vascepa cannot be generalized to any other product: Early stage data show that Vascepa has multiple effects that extend beyond lipid-level modification including antithrombotic effects, antioxidant effects, antiplatelet or anticoagulant effects, membrane-stabilizing effects, effects on stabilization and/or regression of coronary plaque and inflammation reduction."

Sounds a bit familiar to apabetalone's situation, eh? Calling Vascepa a TG-lowering drug is like calling apabetalone a HDL raising drug. Both are true, but are far from the complete story

BearDownAZ